Glycans in antibody drugs may play roles in the antigenicity, pharmacokinetics and high-order structural stability of drugs, which could adversely affect their safety and effectiveness. It is therefore necessary to investigate which glycans are present in antibody pharmaceuticals. Non-uniformity of glycans due to the instability of culture conditions used for antibody drugs is a concern which requires rigorous management of the production process. Here, using the core-shell column AerisTM PEPTIDE XB-C18 and the Nexera X2 ultra high performance liquid chromatograph, we introduce an example of the analysis of antibody drug glycans. For detection, the world-leading sensitivity fluorescence detector, the RF-20Axs was used.